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ARTICLE
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Acute kidney injury (AKI) is considered largely reversible based on the capacity of surviving
tubular cells to dedifferentiate and replace lost cells via cell division. Here we show by
tracking individual tubular cells in conditional Pax8/Confetti mice that kidney function is
recovered after AKI despite substantial tubular cell loss. Cell cycle and ploidy analysis upon
AKI in conditional Pax8/FUCCI2aR mice and human biopsies identify endocycle-mediated
hypertrophy of tubular cells. By contrast, a small subset of Pax2+ tubular progenitors enri-
ches via higher stress resistance and clonal expansion and regenerates necrotic tubule
segments, a process that can be enhanced by suitable drugs. Thus, renal functional recovery
upon AKI involves remnant tubular cell hypertrophy via endocycle and limited progenitor-
driven regeneration that can be pharmacologically enhanced.
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Acute kidney injury (AKI) is a global health concernimpacting ∼13.3 million patients1 and 1.7 million deathsper year2,3. AKI is deﬁned by an acute deterioration of
renal excretory function1–3. If not lethal in the acute phase, AKI is
considered reversible as implied by recovery of urine production
and biomarkers of renal function3. However, even mild AKI
episodes imply a substantial risk for subsequent chronic kidney
disease (CKD)1, but the pathophysiological basis for this
phenomenon remains uncertain4. Indeed, the current patho-
physiological concept involves the assumption that every tubular
epithelial cell (TEC) surviving the injury phase has the potential
to dedifferentiate and proliferate to replace lost cells or even re-
epithelialize denuded tubule segments5,6. This concept has been
evidenced by immunolabelling for cell cycle markers, such as Ki-
67, proliferating cell nuclear antigen (PCNA) or 5-bromo-2′-
deoxyuridine (BrdU) uptake7. As a second concept, tubule
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regeneration may also involve a speciﬁc subset of TECs, referred
to as tubular progenitors8–10. We set three hypotheses: (1) the
overall capacity of tubular regeneration after injury is largely
overestimated; (2) cell cycle markers may not consistently
represent cell division; (3) regeneration is limited to tubular
progenitors and other TECs entering the cell cycle after AKI
undergo endocycle-related hypertrophy.
Results
Function recovery upon AKI masks a substantial TEC loss. To
evaluate TEC loss and regeneration after AKI, we applied a
lineage tracing approach using conditional Pax8.rtTA;TetO.Cre;
R26.Confetti (Pax8/Confetti) mice11, enabling a doxycycline-
induced random labeling of all TECs by permanent recombina-
tion of a single-color-encoding gene (red, yellow, green, or blue
ﬂuorescent proteins, RFP, YFP, GFP, and CFP; Supplementary
Fig. 1a)12. Transient unilateral ischemia reperfusion injury (IRI)
was then induced as detailed in Supplementary Fig. 1b, c. Tubular
necrosis at day 2 was partially restored at day 30 and associated
with some focal interstitial ﬁbrosis (Supplementary Fig. 1d).
Blood urea nitrogen (BUN) was unchanged, even if at day 30 a
signiﬁcant loss-of-kidney weight had occurred (Supplementary
Fig. 1e, f). Since BUN was too insensitive to detect the decline of
kidney function, we directly measured glomerular ﬁltration rate
(GFR). GFR strongly declined at day 1 and partially recovered at
day 14 remaining stable thereafter indicating CKD after AKI
(Fig. 1a). Lineage tracing up to day 30 showed the presence of
single-colored clones in outer stripe of the outer medulla (OSOM)
(Fig. 1b, c). Therefore, all further analyses focused on this area.
Quantitative analysis revealed a substantial and sustained loss-of-
30.5 ± 2.8% of total Confetti-labelled TECs (Fig. 1d). Similar
results were obtained when TEC loss was evaluated after
immunostaining for aquaporin-2 (AQP2) to exclude from the
count collecting ducts (23.8 ± 5.9%; Fig. 1d), or for aquaporin-1
(AQP1), to limit the analysis to proximal TECs up to the thin
descending limb of the Henle’s loop (32.5 ± 7.1%; Fig. 1d and
Supplementary Fig. 1g–i). No transgene leakage was observed in
healthy or ischemic mice (Supplementary Fig. 1j, k). Similar data
were obtained in glycerol-induced AKI, a model of toxic tubule
necrosis, either when we quantiﬁed total Confetti or AQP2−
Confetti TECs (Fig. 1e–h). Thus, function recovery upon AKI
masks a substantial and sustained TEC loss.
A small TEC subset proliferates after AKI. To test the current
dogma of kidney regeneration via mitotic cell division of sur-
viving TECs, we quantiﬁed their progeny. Administration of a
lower doxycycline dose to label few TECs enabled precise clone
counts at day 30 after IRI (Supplementary Fig. 1l, m). Healthy
mice (T0), mice that underwent a prolonged washout for 30 days
(age-matched controls, T30) and sham-operated mice presented a
similar clone size frequency (Fig. 1j; NS, Eq. 1 in Methods). Of
note, the percentage of single cell clones decreased from 92.4 ±
0.9% at T0 to 78.9 ± 0.9% at day 30 after IRI. By contrast, clones
consisting of 2 or more cells increased from 7.4 ± 0.9% at T0 (6.4
± 0.7 of doublets and 1 ± 0.2% of triplets) to 21.1 ± 0.9% at T30
after IRI (11.9 ± 1.5% of doublets, 4.3 ± 0.2% of triplets and 4.9 ±
1.4% ≥4 cells, with single colored clones of up to 11 cells; Fig. 1i, j,
Supplementary Fig. 2, Eq. 1 in Methods). Newly generated cells,
had replaced only 54.1 ± 10.1% of lost AQP2− TECs (Fig. 1k,
Eq. 3 in Methods). The clones observed at day 30 after IRI
represented 21.1 ± 0.9% of those AQP2− survived, but were the
progeny of only 8.6 ± 1.6% of AQP2− TECs present at T0 (Fig. 1l,
Supplementary Fig. 2, Eq. 2 in Methods). Similar results were
obtained in the nephrotoxic AKI model, where 35.4 ± 5.7% of lost
cells were replaced in each kidney (Fig. 1k, Eq. 3 in Methods) and
ultimately derived from 3.5 ± 0.1% of AQP2− TECs present at T0
(Fig. 1l, Eq. 2 in Methods). Together, these results show that upon
AKI only a small TEC subset undergoes mitosis to replace no
more than ∼50% of injured cells.
Kidney tubules contain a distinct Pax2+ cell subset. Using
conditional Pax2.rtTA;TetO.Cre;R26.Confetti (Pax2/Confetti) mice
(Supplementary Fig. 3a), we recently identiﬁed Pax2+ cells of the
Bowman’s capsule as progenitors regenerating podocytes upon
glomerular injury13. These mice exhibited no leakage and Pax2
promoter ﬁdelity as showed in Supplementary Fig. 3b–e and already
previously reported14,15. Pax2+ cells were also found in a scattered
pattern within tubules (Fig. 2a–h) along speciﬁc segments of the
nephron (Fig. 2d). In particular, they represented 1.6 ± 0.5% of
megalin+ TECs in S1 and S2 segments (Fig. 2h), 9.8 ± 0.9% of
AQP1+ TECs in S3 segment (Fig. 2a, e) and 12.3 ± 1.2% of
Tamm–Horsfall Protein+ (THP+) distal TECs (Fig. 2b, f).
Induction of cell labeling followed by 30 days washout or
continued doxycycline exposure for the same period of time
revealed stable numbers of Pax2 cells (Fig. 2i–l). In addition,
induction of cell labeling at 12 weeks of age (Supplementary Fig. 3f)
revealed a number of Pax2+ cells similar to that observed in mice
induced at 5 weeks of age (68.8 ± 4.9 vs. 62 ± 1.2; NS). Thus, Pax2+
TECs are a distinct and stable cell population in mice.
Pax2+ cells show increased survival and clonogenicity after
AKI. To see if and how the Pax2+ TEC subset contribute to
tubule regeneration upon AKI, injured kidneys were subjected to
lineage tracing over 30 days after IRI and nephrotoxic injury
Fig. 1 Only a small TEC subset proliferates after AKI and partially replaces lost TECs. a GFR in ischemic mice (n= 13) normalized on the GFR at baseline
and on sham-operated control group (n= 5). One-way ANOVA post hoc Tukey. b, c Juxtaposed images of a Pax8/Confetti mouse kidney at day 0 (T0,
n= 5) (b) and 30 after IRI (IRI T30, n= 4) (c). Arrows indicate single-colored clones. OSOM outer stripe of outer medulla; ISOM inner stripe of outer
medulla. d Number of Pax8+, Pax8+AQP2−, and Pax8+AQP1+ cells in Pax8/Confetti mice at day 0 (T0, white column, n= 5) and at day 30 after IRI (IRI
T30, gray column, n= 4). Mann–Whitney test. *p < 0.05, **p < 0.01 IRI T30 vs. T0. e BUN in healthy Pax8/Confetti mice (n= 5) and in Pax8/Confetti mice
after nephrotoxic AKI (n= 6). One-way ANOVA post hoc Tukey *p < 0.05 glycerol-treated mice vs. healthy. f GFR in Pax8/Confetti mice after nephrotoxic
AKI (n= 7) normalized on the GFR at baseline and on healthy mice (n= 5). One-way ANOVA post hoc Tukey. g Number of Pax8+ cells in Pax8/Confetti
mice at day 0 (T0, white column, n= 5) and day 30 after nephrotoxic AKI (Gly T30, gray with sparse pattern column, n= 4). Mann–Whitney test *p <
0.05 Gly T30 vs. T0. h Number of Pax8+AQP2− cells in Pax8/Confetti mice at day 0 (T0, white column, n= 5) and day 30 after nephrotoxic AKI (Gly
T30, gray with sparse pattern column, n= 4). Mann–Whitney test *p < 0.05 Gly T30 vs. T0. i Single-colored clones in AQP2− tubules in Pax8/Confetti
mice at day 30 after IRI (n= 4). AQP2 staining is white. j Clone frequency analysis of Pax8+AQP2− cells in Pax8/Confetti mice at day 0 (T0, n= 5), in
age-matched controls (T30, n= 4), in sham-operated mice (n= 4), at day 30 after IRI (IRI T30, n= 4) and at day 30 after nephrotoxic AKI (Gly T30, n=
4). Mann–Whitney test *p < 0.05 IRI T30 vs. T0, T30, sham and Gly T30 vs. T0 and T30. k Percentage of Pax8+AQP2− cells in Pax8/Confetti mice at day
0 (T0, n= 5), at day 30 after IRI (IRI T30, n= 4) and at day 30 after nephrotoxic AKI (Gly T30, n= 4). Mann–Whitney test *p < 0.05 IRI T30 and Gly T30
vs. T0. l Percentage of Pax8+AQP2− clonogenic cells (gray column) in Pax8/Confetti mice at day 30 after IRI (IRI T30, n= 4) and at day 30 after
nephrotoxic AKI (Gly T30, n= 4) vs. day 0 (n= n= 5). The white column is the percentage of Pax8+AQP2− that did not generate clones. Data are mean
± SEM. Scale bars 40 µm. Pax8+= Pax8 lineage-positive cells
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dots) in the proximal tubule, stained by AQP1 (light gray), in the thick ascending limb and in the distal tubule, stained by THP (dark gray), of the nephron.
e–h Representative images of a kidney section in healthy Pax2/Confetti mice showing (n= 4) the distribution of Pax2 lineage-positive cells in S3 segment
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(Supplementary Fig. 4a). BUN and GFR measurements gave
similar results to those obtained in Pax8/Confetti mice (Supple-
mentary Fig. 4b and Fig. 3a). This study revealed single-colored
clones (Fig. 3b–d) up to 10 cells within S3 segments resulting in
an increase number of Pax2+AQP2− TECs per ﬁeld (Fig. 3e; p <
0.05) after IRI. Clone size frequency analysis at T0, T30, and in
sham-operated mice showed similar percentages of clones
(Fig. 3f; NS, Eq. 1 in Methods). Of note, the percentage of
single cell clones at T0 decreased from 97.7 ± 0.2% to 76.4 ± 1.8%
at day 30 after IRI (Fig. 3f, Eq. 1 in Methods). By contrast, clones
consisting of 2 or more cells increased from 2.2 ± 0.2% (only
doublets) to 23.6 ± 1.8% (15.2 ± 0.6% of doublets, 5.1 ± 0.8% of
triplets and 3.3 ± 0.7% ≥4 cells, with single colored clones of up to
10 cells; Fig. 3f, Eq. 1 in Methods section). Accordingly, 30 days
after IRI newly generated Pax2+AQP2− TECs, appeared and
signiﬁcantly increased the total number of Pax2+AQP2− TECs
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in comparison to T0 (Fig. 3g, Eq. 3 in Methods). Following IRI
and expansion of Pax2+ cells, Pax2 immunolabelling was present
also on many TECs not expressing the Confetti reporter, implying
TECs could acquire Pax2 expression upon injury (Supplementary
Fig. 4c). Consistently, many Pax2− immunolabelled cells in Pax8/
Confetti mice were not found clonogenic (Supplementary
Fig. 4d).
The enrichment of Pax2+ TECs labeled by the Confetti
reporter (Fig. 3h) was related to both an increased survival
capacity (Fig. 3i, Eq. 4 in Methods), as well as to a higher
clonogenic capacity (Fig. 3j, Eq. 2 in Methods) in comparison to
other TECs. Indeed, while Pax8+ cells were signiﬁcantly reduced,
Pax2+ cells were expanded in comparison to day 0 (Fig. 3k, Eq. 5
in Methods). Similar results were obtained in nephrotoxic AKI
(Fig. 3l–o and Supplementary Fig. 4e, Eqs. 4, 2 and 5 in Methods).
No transgene leakage was observed in Pax2/Confetti ischemic
mice (Supplementary Fig. 4f). These results demonstrate that
during AKI Pax2+ TECs display increased survival and capacity
to undergo mitosis in comparison to other TECs.
Pax2+ cells regenerate long tubule segments. We then checked
the distribution of Pax2+ clones in the different tubule segments
after immunolabelling for megalin, AQP1, THP, and AQP2
(Fig. 4a–d). The great majority of Pax2-derived clones formed in
the S3 segment and less in the TAL of Henle’s loop (Fig. 4e, Eq. 7
in Methods), the two tubule segments of the outer medulla where
tubule necrosis occurs. By contrast, only few clones formed in the
S1–S2 segments in the cortex or in collecting ducts (Fig. 4e, Eq. 7
in Methods). The percentage of clonogenic cells was not sig-
niﬁcantly different between a 2D and 3D analysis performed in
40 µm thick sections (Fig. 4f, Eq. 2 in Methods). However, the 2D
analysis slightly overestimated the percentage of clonogenic cells
due to long clones being mistakenly counted as several smaller
ones (Fig. 4f). Indeed, 2D assessment allowed identiﬁcation of
clones of up to 10 cells, while 3D analysis revealed sin-
gle colored Pax2+ clones up to 98 cells regenerating long tubule
segments (Fig. 4g–i and Supplementary Movie 1). These results
demonstrate that pre-existing populations of Pax2+ cells regen-
erate necrotic tubule segments in the injured outer medulla.
Drugs stimulating regeneration after AKI act selectively on
Pax2+ TECs. We then evaluated if proliferation is limited to
Pax2+ cells or involves also other TECs. To this aim, we treated
Pax2/Confetti mice with drugs that were previously reported to
increase TEC proliferation and to improve tissue regeneration
following AKI16–19, i.e., the histone deacetylase inhibitors
(HDACi) trichostatin (TSA) and 4-phenylbutyrate (4-PBA)
(Supplementary Fig. 5a–d). Treatment starting 24 h after IRI
resulted in a sustained recovery of GFR in comparison to mice
treated with vehicle, which remained with persistently impaired
GFR, i.e., CKD (Fig. 5a, b). A better reconstitution of tubular
integrity was also observed (Fig. 5c, Supplementary Fig. 5e–g),
consistent with previous results16–19. TSA and 4-PBA both
increased TEC number in comparison to vehicle. Of note,
86.4 ± 4.5% and 64.7 ± 5.5% of TEC loss were restored in TSA-
and 4-PBA- treated mice, respectively (Fig. 5d).
Strikingly, the increased TEC number was related to a selective
expansion of Pax2+ TECs (Fig. 5e, Eq. 6 in Methods), that
proliferated extensively, as demonstrated by the signiﬁcant
increase of Pax2+ cells included in clones (Fig. 5f). By contrast,
the number of other TECs was unchanged (Fig. 5e). Representa-
tive images are shown (Fig. 5g–k). These results show that HDAC
inhibitors, that stimulate tubular regeneration after AKI, act
selectively on Pax2+ cells.
Cell cycle markers do not predict cell division after AKI. The
ﬁnding that only Pax2+ TECs divide upon IRI was in conﬂict
with immunolabelling for Ki-67 (expressed from late G1 to
mitosis7, Fig. 6a–d), or PCNA, (expressed from late G1 to early
G220, Fig. 6e–h). Indeed, we found diffuse tubular Ki-67 (Fig. 6b,
d), as well as PCNA (Fig. 6f, h) positivity 2 days after injury
suggesting many more TECs proliferate than actually proven by
clone analysis in Pax8/Confetti mice. To clarify this apparent
inconsistency we crossed Pax8-, as well as Pax2.rtTA;TetO.Cre;
mice with mice harboring the ﬂuorescent ubiquitin-based cell
cycle indicator (FUCCI2) Cre-dependent reporter (Supplemen-
tary Fig. 6a, b), which consists of two ﬂuorescent proteins whose
expression alternates based on cell cycle phase: mCherry-hCdt1
(red color), expressed in G1, and mVenus-hGem (green color),
expressed in S/G2/M21 (Supplementary Fig. 6c). Cells can also
appear as yellow at the G1/S boundary.22 Experimental designs
are detailed in Supplementary Fig. 6d, e.
Based on Pax8/FUCCI2 mice evaluated by confocal micro-
scopy (Fig. 6i–k and Supplementary Fig. 6f–h) few TECs
appeared in S/G2/M (mVenus+) at day 2 after IRI despite
widespread tubular Ki-67 positivity (13.2 ± 3.4% vs. 47.1 ± 9.2%;
p < 0.05 Mann–Whitney test; Fig. 6j, l vs. Fig. 6b, d). Interestingly,
when Pax2/FUCCI2 mice were evaluated by confocal microscopy
(Fig. 6m–o and Supplementary Fig. 6i–k), the percentage of
cycling cells over the total of Pax2+ FUCCI2+ cells was higher
(40.6 ± 1.7%; Fig. 6n, p), but the number per ﬁeld was comparable
to that of the Pax8/FUCCI mice (10.7 ± 0.4 in Pax2/FUCCI2 mice
Fig. 3 Pax2 lineage-positive cells show increased survival and proliferative capacity in comparison to other TECs after AKI. a GFR in Pax2/Confetti mice
after ischemic AKI (n= 9) normalized on the GFR at baseline and on sham-operated control group (n= 5). One-way ANOVA post hoc Tukey. b
Juxtaposed confocal images of a kidney section in Pax2/Confetti mice at day 30 after IRI (n= 5). Arrows indicate single colored clones. Scale bars 40 µm.
c, d Single colored clones in AQP2− tubules in Pax2/Confetti mice at day 30 after IRI (n= 5). AQP2 staining is white. Scale bars 20 µm. e Number of Pax2
+AQP2− TECs in Pax2/Confetti mice at day 0 (T0, n= 4), in age-matched controls (T30; n= 5), in sham-operated mice (sham; n= 5) and at day 30 after
IRI (IRI T30, n= 5). Mann–Whitney test *p < 0.05 IRI T30 vs. T0, T30 and sham. f Clone frequency analysis of Pax2+AQP2− cells in Pax2/Confetti mice
at day 0 (T0, n= 4), in age-matched controls (T30, n= 5), in sham-operated mice (sham; n= 5) and at day 30 after IRI (IRI T30, n= 5). Mann–Whitney
test *p < 0.05 IRI T30 vs. T0, T30, and sham. g Percentage of Pax2+AQP2− cells in Pax2/Confetti mice at day 0 (T0, n= 4) and 30 after IRI (IRI T30,
n= 5). h Percentage of Pax2+AQP2− TECs vs. AQP2− TECs in Pax2/Confetti mice at day 0 (T0, n= 4), in age-matched controls (T30, n= 5), and at day
30 after IRI (IRI T30, n= 5). Mann–Whitney test *p < 0.05 IRI T30 vs. T0 and T30. i Percentage of lost Pax2+AQP2− TECs (n= 5) and Pax8+AQP2−
TECs (n= 5) at IRI T30 vs. T0. Mann–Whitney test *p < 0.05. j Percentage of Pax2+AQP2− (n= 5) and Pax8+AQP2− TECs (n= 5) that generated
clones at IRI T30 vs. T0. Mann–Whitney test *p < 0.05. k Percentage of Pax2+AQP2− (n= 5) and Pax8+AQP2− TECs (n= 5) at IRI T30 vs. T0. l GFR in
Pax2/Confetti mice after nephrotoxic AKI (n= 8) normalized on the GFR at baseline and on healthy mice (n= 5). One-way ANOVA post-hoc Tukey. m
Percentage of lost Pax2+AQP2− TECs (n= 6) in Pax2/Confetti and of lost Pax8+AQP2− (n= 4) in Pax8/Confetti mice at day 30 after nephrotoxic AKI
vs. T0. Mann–Whitney test *p < 0.05. n Percentage of Pax2+AQP2− (n= 6) and Pax8+AQP2− TECs (n= 4) that generated clones at day 30 after
nephrotoxic AKI vs. T0. Mann–Whitney test *p < 0.05. o Percentage of Pax2+AQP2− (n= 6) and Pax8+AQP2− TECs (n= 4) at day 30 after nephrotoxic
AKI vs. T0. Data are mean ± SEM. Pax2+= Pax2 lineage-positive cells, Pax8+= Pax8 lineage-positive cells. For calculation of ﬁgures i–k, m–o see
Methods section and representative calculations in Pax2/Confetti mice in Supplementary Methods
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vs. 10.9 ± 0.3 in Pax8/FUCCI2 mice, NS) (Fig. 6n vs. Fig. 6j).
These results suggested that numerous TECs entered the cell cycle
but only few progressed toward the G2/M phase, i.e., mitosis.
Both in Pax8/FUCCI2 and Pax2/FUCCI2 mice TECs were
selectively labeled, as shown in Fig. 6i–k and Fig. 6m–o with
Phalloidin staining and as previously reported23,24. No transgene
leakage was observed in healthy or ischemic mice (Supplementary
Fig. 6l–q). We thus performed immunolabelling for a marker
commonly considered to label only cells in the G2/M phase,
serine 10-phosphorylated histone H3 (p-H3)25–27. As expected, a
lower percentage of TECs at day 2 was p-H3+ in comparison to
Ki-67 (11.9 ± 1.1% vs. 47.1 ± 9.2%, p < 0.05, Supplementary Fig. 6r
and Fig. 6d). P-H3+ TECs were mostly mVenus+, conﬁrming
that they were in G2/M (Fig. 6q, s). However, unexpectedly, also
some Pax8+ TECs in G1 (mCherry+) were labeled (Fig. 6q). At
day 30, mCherry+p-H3+ cells strongly increased, representing
about a half of FUCCI2+p-H3+ TECs (Fig. 6r, s). By contrast, in
Pax2/FUCCI2 mice, p-H3 mostly co-labeled mVenus-expressing
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cells (Fig. 6t–v). This implies that Pax2+p-H3+ cells were truly
in G2/M phase. These results document that Ki-67, PCNA, and
p-H3 do not reliably indicate TEC proliferation after AKI.
Pax8+ TECs endocycle while Pax2+ cells complete mitosis.
The aforementioned data, together with the results obtained with
the Confetti models, consistently suggested that most TECs might
undergo alternative cell cycles without cell division. Indeed such
alternative cycles, e.g., endoreplication cycles or endocycles, have
recently been reported to drive polyploidy and hypertrophy upon
tissue injury28. To evaluate this possibility in AKI, we combined
DNA content analysis with detection of FUCCI2 ﬂuorescence by
ﬂow cytometry. Indeed, using this approach, G2/M diploid cells,
which express mVenus and represent truly cycling cells can be
distinguished from G1 polyploid cells which express mCherry
and instead represent mononucleated endoreplicating cells
(Fig. 6w–z). Pax8/FUCCI2 mice 2 days after IRI showed 9.8 ±
0.7% of Pax8+ TECs in S phase, but only 2 ± 0.5% in G2/M phase
(Fig. 6w, y). Lineage tracing of mice for 30 days showed a con-
siderable increase of Pax8+ TECs cells that expressed mCherry
but displayed a polyploid DNA content (≥4C) (2.1 ± 0.1% at day
2 vs. 13.5 ± 1.4% at day 30, p < 0.05, Mann–Whitney test; Fig. 6w,
y). By contrast, cells with an abnormal DNA content were not
observed in Pax2/FUCCI2 mice, either at 2 or 30 days (Fig. 6x, z).
Rather, 2 days after IRI 35 ± 4.8% of Pax2+ cells were in the S
phase, suggesting a higher proliferation capacity than Pax8+ cells
(Fig. 6y, z). The gating strategy used to analyse FUCCI2+ cells
and to avoid counting cell doublets as a potential source of
artifacts is shown in Supplementary Fig. 7. Given our extremely
conservative gating strategy, we certainly underestimated the
percentage of endocycling cells. Similar results were obtained
after deleting AQP2+ cells from the analysis (Supplementary
Fig. 7b–e). These results show that Pax2+ cells frequently and
efﬁciently divide, while other TECs endocycle into polyploid
mononuclear TECs.
Pax2+ cells proliferate while other TECs undergo hypertrophy.
To validate these results, we used two further transgenic mouse
lines, based on the FUCCI2aR reporter, a recent advancement of
the FUCCI2 which produces iso-stoichiometric quantities of both
FUCCI probes expressed during all the cell cycle, with higher
sensitivity and labeling of the cells during all the cell cycle
phases29.
The generation of Pax8.rtTA;TetO.Cre;FUCCI2aR, as well as
Pax2.rtTA;TetO.Cre;FUCCI2aR transgenic mouse lines, experi-
mental design and controls are detailed in Methods and in
Supplementary Fig. 8. Both transgenic lines showed a percentage
of induction higher than 90%.
The experimental procedure is summarized in Fig. 7a. Total
renal cell suspensions were analysed by MacsQuant ﬂow
cytometry at time 0, day 2 and day 30 after IRI. As expected,
the percentage of Pax8/FUCCI2aR-labeled tubular cells over total
renal cells was about 10 times higher than that of Pax2/
FUCCI2aR cells (Fig. 7b–j and Supplementary Fig. 9). However,
this was only related to a higher percentage of mCherry+ cells, as
the percentage of mVenus+ cells was similar (Fig. 7b–j and
Supplementary Fig. 9), suggesting that virtually only Pax2+ cells
divide after AKI. The MacsQuant ﬂow cytometer also auto-
matically quantiﬁed the number of cells/μl of the different
populations contained in the total renal cell suspensions. Counts
conﬁrmed the massive TEC loss in Pax8/FUCCI2aR mice 2 days
after IRI, that was only partially recovered after 30 days as found
before (Fig. 7k). Interestingly, the number of newly generated
cells at day 30 in comparison to day 2 in Pax8/FUCCI2aR and
Pax2/FUCCI2aR mice was similar (Fig. 7l). Pax2/FUCCI2aR cell
numbers at day 30 were signiﬁcantly expanded in comparison to
day 2 (Fig. 7k), passing from 12.6 ± 1.4% of Pax8/FUCCI2aR total
cells at day 0 to 19.5 ± 2.2% at day 2 and to 28.9 ± 3.4% at day 30
(Fig. 7m). Strikingly, absolute counts showed that the number of
proliferating cells (mVenus+ and mCherry+mVenus+) in Pax8/
FUCCI2aR and in Pax2/FUCCI2aR mice was virtually identical
at all time points analysed (Fig. 7n), demonstrating that only Pax2
+ cells divide after AKI. Confocal microscopy showed expression
of KIM-1 protein at day 30 by 71.7 ± 4.7% of Pax8+mCherry+
TECs, vs. only 2 ± 1.2% of Pax2+mCherry+ TECs, further
underlining the different survival capacity of Pax2+ cells in
comparison to other TECs (Supplementary Fig. 8i, m).
We then analysed the occurrence and distribution of endo-
cycle. Consistent with results obtained in FUCCI2 mice,
endocycling cells were only observed in Pax8/FUCCI2aR mice
(Fig. 7o–q). In addition, 27.9 ± 4.6% of LTA+ proximal tubular
cells in S1–S2 segments were p-H3+ mCherry+, representing
endocycling cells, in comparison to 1.8 ± 0.8 of LTA+ proximal
tubular cells that were mVenus+, the only truly dividing cells
(Fig. 7r–t). Immunolabelling for AQP2 showed that the great
majority of endocycling cells localized in the cortex (22.3 ± 3.4%
in the cortex vs. 7.8 ± 2.2% in the OSOM), while the majority of
truly proliferating cells localized in the OSOM (9.2 ± 1.6% in the
OSOM vs. 3.1 ± 1.1% in the cortex, Fig. 7u). Endocycling cells in
G1 (Pax8+mCherry+p-H3+TECs) displayed an increased size in
comparison to cycling cells in G1 (Pax8+mCherry+p-H3−
TECs) as conﬁrmed by comparing their cell surface area by
confocal microscopy (Fig. 7v, w).
Taken together, Pax2+ cells in the OSOM are the cells that
regenerate injured tubules after AKI by mitotic cell division, while
other TECs of the S1 and S2 segments rather enter endocycles to
undergo hypertrophy. Both mechanisms may compensate for the
irreversible loss-of-TECs occurring during AKI.
Endocycle is detected in kidneys of patients with CKD after
AKI. To verify the presence of endocycling cells in human, we
examined kidney biopsies from 10 cases of CKD after AKI and 5
healthy controls (Table 1). To detect endocycling cells in human,
we applied the same strategy previously validated in the mouse,
and searched for p-H3+ cells in G1 phase, the latter identiﬁed by
Fig. 4 Pax2 lineage-positive cells regenerate long tubule segments. a Representative image of a kidney section showing single-colored clones in
S1–S2 segments of proximal tubule as demonstrated by staining with anti-megalin antibody (white) in Pax2/Confetti mice at day 30 after IRI (n= 5). Scale
bar 20 µm. b, c Representative images of a kidney section showing single-colored clones in S3 segment of proximal tubule as demonstrated by staining with
anti-AQP1 antibody (white) in OSOM of Pax2/Confetti mice at day 30 after IRI (n= 5). Scale bars 20 µm. d Representative image of a kidney section
showing single-colored clones in thick ascending limb as demonstrated by staining with anti-THP antibody (white) in Pax2/Confetti mice at day 30 after IRI
(n= 5). Scale bar 20 µm. e Frequency of Pax2+ clones in S1–S2 segment of proximal tubules (Pax2+ Megalin+ clones, n= 5), in S3 segment of proximal
tubules (Pax2+AQP1+ clones, n= 7), in thick ascending limbs (TAL, Pax2+THP+ clones, n= 7) and in the collecting ducts (Pax2+AQP2+ clones, n= 7)
at day 30 after IRI. Mann–Whitney test. **p < 0.01 S3 vs. S1–S2 and collecting ducts, *p < 0.05 S3 vs. TAL and TAL vs. collecting ducts. f Percentage of
clonogenic cells per ﬁeld in 2D vs. 3D analysis in Pax2/Confetti and in Pax8/Confetti mice at day 30 after IRI vs. T0. (n= 5 Pax2/Confetti mice and n= 5
Pax8/Confetti mice). Mann–Whitney test NS. g–i 3D reconstruction of single-colored clones in Pax2/Confetti mice at day 30 after IRI (n= 5). DAPI
counterstains nuclei (white). Scale bars 50 µm. Data are mean ± SEM. Pax2+= Pax2 lineage-positive cells, Pax8+= Pax8 lineage-positive cells
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CDK4 positivity, a kinase selectively expressed along the nuclear
membrane in cells in G1 cell cycle phase30. Triple positivity of
nuclear membrane CDK4, nuclear p-H3, and the proximal tubule
marker Lotus Tetragonolobus Lectin (LTA) revealed that 44.9 ±
7.6% of proximal TECs in biopsies vs. 8.5 ± 3.5% in control
kidneys were endocycling cells (Fig. 8a–e). By contrast, 7.9 ± 1.3%
of proximal TECs in biopsies were single labeled for p-H3 vs. 3.8
± 1.7% in control kidneys suggesting these were the only truly
cycling cells. When endocycling cells were evaluated on all the
tubular cells by colabelling for Phalloidin, the percentage declined
to 18 ± 3.1% in biopsies vs. 2.9 ± 2.2% in control kidneys, sug-
gesting endocycling cells are highly enriched in cortical proximal
tubules (Fig. 8f). Consistently, ﬂuorescence in situ hybridization
for the Y chromosome on Phalloidin-stained biopsies detected
19.1 ± 4.3% of TECs with two, and 1.9 ± 0.7% of TECs with three
or more Y chromosomes but a single nucleus (Fig. 8g, h). These
cells were not observed in healthy controls.
These observations validate the experimental data from mice in
patients with CKD after AKI and show that the majority of TECs
stained by “proliferation markers” undergo endocycle-mediated
hypertrophy.
Discussion
In this study, we questioned the current paradigm that functional
recovery after AKI relates to a regenerative capacity of all TECs5,6.
Indeed, our data demonstrate that: (1) AKI involves a permanent
loss of TECs even when GFR recovery occurs; (2) Pax2+ TECs
are endowed with higher resistance to death and clonogenic
capacity and are responsible for both spontaneous and drug-
enhanced regeneration of necrotic tubule segments after AKI; (3)
Only Pax2+ TECs complete mitosis, while other TECs rather
undergo endoreplication-mediated hypertrophy; (4) Endocycle is
a dominant TEC response upon AKI also in humans.
Previous studies concluded on a diffuse proliferative response
of surviving TECs based on immunolabelling for cell cycle pro-
liferation markers, a technical approach obviously unable to
verify cell division5–7,25. Indeed, TECs with mitotic ﬁgures are
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rarely found in AKI kidneys31. Using three independent techni-
ques, we found that only a small subset of TECs undergos mitosis
and contributes to kidney regeneration. To address the dis-
crepancy between widespread positivity of proliferation markers
and limited clonal cell division, we ﬁrst evaluated the possibility
that the tubule contains a progenitor population deputed to
replacement of lost TECs using lineage tracing of Pax2+ cells, a
putative intratubular progenitor population. Pax2+ cells are
mostly located in the S3 segment and the distal tubule, the tubule
segments injured in ischemic or toxic AKI32, reminiscent of
another subset of possible tubular progenitors characterized by
Sox9 expression33,34. Our lineage tracing strategy unambiguously
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excluded upregulation of Pax2 expression upon AKI as a con-
founding factor. Rather, Pax2+ cells represented a distinct tub-
ular cell subpopulation and were more resistant to death,
explaining why some TECs survive an injury killing most of the
other TECs. This was further highlighted by their lack of
expression of the TEC injury marker KIM-1 that was instead
largely upregulated by other TECs upon IRI. Moreover, Pax2+
cells displayed high clonogenic activity, and were the only TECs
to efﬁciently complete mitosis after AKI, regenerating even long
tubule segments. Indeed, 3D evaluation of regenerated tubule seg-
ments revealed very long Pax2+ clones that were not visible with
the classical 2D analysis that underestimated the length of clones.
Interestingly, being unable to detect long clones, the 2D analysis
slightly overestimated the percentage of dividing TECs, even if the
difference was not statistically signiﬁcant when 40 µm thick 3D
sections were compared with 2D images. This suggests that the
percentage of dividing TECs would likely even be lower when
analyzing the whole organ. Taken together these results indicate
that new tubular cells arise exclusively from pre-existing labeled
Pax2+ cells that expand regenerating the entire S3 or distal tubule
segment and therefore behaving as progenitor cells35.
Our results may appear in conﬂict with those of other studies
reporting widespread TEC proliferation with lineage tracing
techniques upon IRI36,37. However, although we report a per-
centage of dividing TECs after IRI of only 8.3%, the clone fre-
quency observed in our study in the IRI model at the end of the
lineage tracing period is comparable to the one reported by
Kusaba et al.36 for the 26 min IRI model (21.1 ± 0.9% vs. 27.4%).
The difference in our conclusions is related to our demonstration
for the ﬁrst time that in addition to proliferation, two more
phenomena occur after AKI: massive tubular cell loss and
endoreplication. Indeed persistent cell loss, enriching dividing
clones when calculated over the total number of TECs remained
at the end of the lineage tracing period, leads to a profound
overestimation of dividing cell number. This phenomenon is
explained in detail in Supplementary Fig. 2. In addition, endo-
cycling cells are labeled by cell cycle activation markers such as
PCNA or KI-67, representing a further cause of overestimation.
Refering to these markers inappropriately as "proliferation mar-
kers" now appears as a major reason for invalid conclusions.
Indeed, the detection of irreversible TEC loss and endocycle of
surviving TECs requires the combination of clonal lineage tra-
cing, as well as cell cycle plus DNA content analysis, as done in
this study. Endoreplication cycles (endocycles) are cell cycle
variants repeatedly proceeding from G1 to S without passing
mitosis and that can occur in differentiated cells28. For example,
during liver homeostasis, hepatocyte progenitors remain diploid,
while differentiated hepatocytes become polyploid via endor-
eplication35. However, polyploid hepatocytes are multinucleated,
while after injury polyploid TECs remain mononucleated
and hence cannot be detected with standard tools38,39. Combining
FUCCI2 transgenic labeling of cell cycle phase with analysis of
DNA content by ﬂow cytometry, as reported by Ganem et al.39, we
discovered that upon AKI the majority of TECs undergoes
endocycle-mediated hypertrophy. These results challenge the cur-
rent paradigm of widespread TEC proliferation contributing to
kidney regeneration after AKI and rather imply that TEC
endocycle-mediated hypertrophy enhances kidney function recov-
ery after injury. Consistently, in Drosophila melanogaster, com-
pensatory cellular hypertrophy involves endoreplication40. Indeed,
the increased DNA content allows a higher transcription capacity
that can facilitate an increase in cell size28,40, as observed in our AKI
models.
Thus, the results of this study rather suggest that the majority
of TECs entering the cell cycle after AKI undergoes hypertrophy
following TEC loss, conceptually similar to hypertrophy of
remaining podocytes upon podocyte loss41. Kidney regeneration
occurs only via a limited clonal response from TEC progenitors
resulting in a net TEC loss, implying irreversible nephron loss
and subsequent CKD. The more cells are lost, the earlier CKD
becomes clinically apparent. Since TEC hypertrophy sustains
only function but not tissue regeneration, the presence of endo-
cycling TECs can serve as an indirect indicator of irreversible
TEC loss and potentially as a prognostic indicator of the risk for
CKD progression, as suggested by their detection in biopsies of
patients that developed CKD after an AKI episode.
Finally, the results of this study propose tubular progenitors as
a target for treatment of AKI. Indeed, treatment of mice with
drugs that were previously reported to improve tissue regenera-
tion following AKI16–19, showed that their effect resulted from
Pax2+ progenitor proliferation that avoids development of tissue
ﬁbrosis and CKD.
In conclusion, the renal response to AKI involves two crucial
mechanisms: (1) endocycle-mediated hypertrophy of surviving
TECs that contributes to recover renal function despite signiﬁcant
loss of renal mass; (2) survival and mitosis of tubular progenitors
that provide TEC regeneration. These data challenge the current
paradigm of kidney regeneration upon AKI and identify Pax2+
progenitors as the cellular source of a limited intrinsic regen-
erative capacity of kidney tubules. Instead, endocycle-mediated
hypertrophy and persistent tubular cell loss are the predominant
features after AKI. Therapeutic targeting of tubule progenitors
could be a valuable strategy to improve long-term AKI outcomes.
Methods
Pax8/Confetti mice and Pax2/Confetti mice. The Pax8.rtTA;TetO.Cre;R26.
Confetti (Pax8/Confetti) mice or the Pax2.rtTA;TetO.Cre;R26.Confetti (Pax2/
Confetti) mice were developed on a full C57BL/6 background by crossing the
Fig. 6 Cell cycle markers misrepresent proliferation after AKI because numerous TEC endocycle. a–c Ki-67+ (blue) Phalloidin+ (purple) tubules at day 0
(a), 2 (b) and 30 after IRI (c) (n= 3 per group). d Percentage of Ki-67+ cells over Phalloidin+ TECs at T0, IRI T2, and IRI T30 (n= 3 per group). e–g PCNA
+ cells at T0 (e), IRI T2 (f), and IRI T30 (g) (n= 5 per group). h Percentage of PCNA+ cells over TECs at T0, IRI T2, and IRI T30 (n= 5 per group). i–k
mCherry+ cells (red) and mVenus+ cells (green) in Pax8/FUCCI2 mice at T0 (i), IRI T2 (j), and IRI T30 (k) (n= 4 per group). Phalloidin staining is white.
l Percentage of mCherry+ cells, mVenus+ cells and mCherry+mVenus+ cells in Pax8/FUCCI2 mice at T0, IRI T2, and IRI T30. (n= 4 per group). m–o
mCherry+ cells (red) and mVenus+ cells (green) in Pax2/FUCCI2 mice at T0 (m), IRI T2 (n) and IRI T30 (o) (n= 4 per group). Phalloidin staining is
white. p Percentage of mCherry+ cells, mVenus+ cells and mCherry+mVenus+ cells in Pax2/FUCCI2 mice at T0, IRI T2, and IRI T30. (n= 4 per group).
q, r mCherry+ cells (red), mVenus+ cells (green) and p-H3+ cells (blue) in Pax8/FUCCI2 mice at IRI T2 (q) and IRI T30 (r) (n= 4 per group). q′, r′
Details indicated by arrowheads and asterisks in q and r. s Percentage of p-H3+mCherry+ cells and p-H3+mVenus+ cells in Pax8/FUCCI2 mice at IRI T2
and IRI T30. (n= 4 per group). t, u mCherry+ cells (red), mVenus+ cells (green) and p-H3+ cells (blue) in Pax2/FUCCI2 mice at IRI T2 (t) and IRI T30
(u) (n= 4 per group). t′, u′ Details indicated by arrowheads in t and u. v Percentage of p-H3+mCherry+ cells and p-H3+mVenus+ cells in Pax2/FUCCI2
mice at IRI T2 and IRI T30. (n= 4 per group). w, x Cell cycle distribution of mCherry+, mVenus+, and mCherry+mVenus+ cells in Pax8/FUCCI2 mice (w)
and Pax2/FUCCI2 mice (x) at IRI T2 (n= 4, left) and at IRI T30 (n= 5, right). Representative experiments are shown. y, z Percentage of cells over total
Pax8/FUCCI2 cells (y) and over total Pax2/FUCCI2 cells (z) at IRI T2 (n= 4) and IRI T30 (n= 5). Data are mean ± SEM. Scale bars 20 µm. DAPI (white)
counterstains nuclei. T0= day 0, IRI T2= day 2 after IRI, IRI T30= day 30 after IRI
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Confetti strain Gt(ROSA)26Sortm1(CAG-Brainbow2.1)Cle/J with the TetO.Cre strain B6.
Cg-Tg(TetO-Cre)1Jaw/J, both purchased from the Jackson Laboratory (Bar Harbor,
ME, USA). Double transgenic mice were then crossed with a Pax8.rtTA mouse (B6.
Cg-Tg(Pax8-rtTA2S*M2)1Koes/J, Jackson Laboratory) or with a Pax2.rtTA
mouse14, to obtain a triple transgenic inducible mouse model. Mice were geno-
typed and only triple hemizygous mice were used in this study.
Reporter transgene recombination was induced at 5 weeks of age by
administration of 2 mg/ml or 0.25 mg/ml doxycycline hyclate (Sigma-Aldrich, St.
Louis, MO, USA) for Pax8/Confetti mice and 2 mg/ml doxycycline hyclate for
Pax2/Confetti mice in drinking water additioned with 2.5% sucrose (Sigma-
Aldrich) for 10 days. Doxycycline administration induces a permanent
recombination of a single color encoding gene (red, yellow, green, or blue
ﬂuorescent proteins, RFP, YFP, GFP, and CFP), with GFP cells occurring at lower
frequency than other colors12. Further recombination outcome may also result in
no ﬂuorescent reporter labeling in Cre-expressing cells. Following the induction,
mice were kept in a washout period of 1 week and were then killed (day 0, T0, n=
5 for Pax8/Confetti mice induced with 2 mg/ml doxycycline hyclate, n= 5 for
Pax8/Confetti mice induced with 0.25 mg/ml doxycycline hyclate and n= 4 for
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Pax2/Confetti mice) while another group was held in washout for an additional
30 days (T30) and then mice were killed (n= 5 for Pax2/Confetti mice, n= 4 Pax8/
Confetti mice induced with 0.25 mg/ml doxycycline hyclate). An additional group
was induced with doxycycline for 10 days and was maintained for an additional
37 days in continuous induction (doxycycline T30) (Pax2/Confetti mice n= 4).
Another group of Pax2/Confetti mice (n= 3) was induced at 12 weeks of age for
10 days, then it was kept in a washout period of 1 week and then it was killed. In all
these groups the number of male and female mice was equally distributed. Another
experimental group, following the induction and the washout period, underwent a
unilateral IRI of 30′ or an intramuscular injection with hypertonic glycerol and was
then killed at day 30 (n= 16 for Pax8/Confetti, n= 11 for Pax2/Confetti). Sham-
operated mice (n= 5 Pax2/Confetti, n= 4 Pax8/Confetti mice) underwent the
same surgical procedure of ischemic mice, but did not experienced left renal artery
clamping and did not suffered of ischemia.
An additional group of Pax2/Confetti mice were induced with doxycycline for
10 days and after the washout period mice underwent a unilateral IRI of 30′.
Twenty-four hour after injury, mice were treated with HDACi, trichostatin (TSA,
Sigma-Aldrich) 0.5 mg/Kg/day in 40 µL DMSO for 3 weeks i.p. (n= 4) or 4-
phenylbutyrate (4-PBA, Sigma-Aldrich) 1 gr/Kg/day for 3 weeks in drinking water
(n= 4). In a control group (n= 4), mice were treated with DMSO for 3 weeks.
Mice were killed at day 30. Animals with identical genotype and similar age, were
assigned to experimental groups in a blinded manner.
To verify if the transgenic system exhibited any type of leakage or non-speciﬁc
transgene expression, Pax8/Confetti and Pax2/Confetti mice without induction
were killed at T0 and at day 30 after IRI (n= 3 for each transgenic mouse at each
time point).
All animals were killed by CO2 chamber and kidneys were collected, incubated
in 4% paraformaldehyde (PFA, Sigma-Aldrich) in PBS (Sigma-Aldrich) for 2 h at 4
°C followed by immersion in a 15% sucrose solution in PBS for 2 h at 4 °C and,
subsequently, in a 30% sucrose solution in PBS overnight at 4 °C, then frozen.
Pax8/FUCCI2 mice and Pax2/FUCCI2 mice. To visualize the cell cycle pro-
gression of Pax2+ and Pax8+ cells, Pax2.rtTA;TetO.Cre;R26.FUCCI2 (Pax2/
FUCCI2) or Pax8.rtTA;TetO.Cre;R26.FUCCI2 (Pax8/FUCCI2) mouse models were
employed. To create the two strains, we crossed Pax2.rtTA;TetO.Cre or Pax8.rtTA;
TetO.Cre mice with both R26R-mCherry-hCdt1(30/120) (CDB0229K) and R26R-
mVenus-hGem(1/110) (CDB0230K) mice (both obtained from CDB Laboratory for
Animal Resources and Genetic Engineering, RIKEN Kobe, Japan, http://www.cdb.
riken.jp/arg/reporter_mice.html), which combined constitute the FUCCI2 system.
We thus obtained quadruple transgenic mice in a full C57BL/6 background that
were genotyped as reported in “Genotyping” paragraph.
In the resulting mice, following doxycycline administration, Pax2 or Pax8
promoter drives the expression of the ﬂuorescent protein mCherry-hCdt1 (30/120)
(red) in nuclei of cells in G1 phase, and of the ﬂuorescent protein mVenus-hGem
(1/110) (green) in nuclei of cells in S/G2/M phase. Cells can also appear as yellow at
the G1/S boundary, but this is a very short event and thus yellow cells are rare. To
induce reporter expression, at 5 weeks of age male mice were treated with 2 mg/ml
of doxycycline in 2.5% sucrose water ad libidum, then were kept in a washout
period of 1 week (T0, Pax2/FUCCI2 n= 4, Pax8/FUCCI2 n= 4). The percentage of
induction was deﬁned in healthy mice as the number of Pax8-lineage-positive cells
expressing mCherry or mVenus on the total number of tubular cells per ﬁeld. After
the washout period mice underwent a unilateral IRI of 30 min (same procedure
performed in Confetti mice), and were then killed at day 2 (Pax2/FUCCI2 n= 8,
Pax8/FUCCI2 n= 8) and at day 30 (Pax2/FUCCI2 n= 9, Pax8/FUCCI2 n= 12).
Animals with identical genotype and similar age were assigned to experimental
groups in a blinded manner. To verify if the transgenic system exhibited any type
of leakage or non-speciﬁc transgene expression, Pax8/FUCCI2 and Pax2/FUCCI2
mice without induction were killed at T0 and at day 30 after IRI (n= 3 for each
transgenic mouse at each time point).
All animals were killed by CO2 chamber and kidneys were collected and
evaluated by the confocal microscopy or by ﬂow cytometry. To perform confocal
analysis, kidneys were processed as described for Confetti mice.
Pax8/FUCCI2aR mice and Pax2/FUCCI2aR mice. The FUCCI2aR represents a
signiﬁcant advancement on the FUCCI model, since it produces iso-stoichiometric
quantities of both FUCCI probes without the existence of the “dark phase”at the
end of each cell cycle. This newer model has the advantage that both probes are
always expressed in the same ratio, simplifying the detection of green–red transi-
tion and making it possible to directly trace and quantify the number of labeled
cells by ﬂow cytometry using the MACSQuant software (Miltenyi Biotec S.r.l.,
Bologna, Italy). For this reason, we crossed Pax8.rtTA;TetO.Cre; as well as Pax2.
rtTA;TetO.Cre; mice with mice harboring the Fluorescent Ubiquitin-based Cell
cycle Indicator (FUCCI2aR) Cre-dependent reporter (European Mouse Mutant
Archive (EMMA), INFRAFRONTIER-I3, Neuherberg-München, Germany), which
consists of a bicistronic Cre-activable reporter of two ﬂuorescent proteins whose
expression alternates based on cell cycle phase: mCherry-hCdt1 (30/120) (red),
expressed in nuclei of cells in G1 phase, and mVenus-hGem (1/110) (green),
expressed in nuclei of cells in S/G2/M. We thus obtained triple transgenic mice in a
full C57BL/6 background that were genotyped as reported in “Genotyping”
paragraph.
In the resulting mice, following doxycycline administration, Pax2 or Pax8
promoter drives the expression of the ﬂuorescent protein mCherry-hCdt1 (30/120)
(red) in nuclei of cells in G1 phase, and of the ﬂuorescent protein mVenus-hGem
(1/110) (green) in nuclei of cells in S/G2/M phase. Cells can also appear as yellow at
the G1/S boundary, but this is a very short event and thus yellow cells are rare.
To induce reporter expression, at 5 weeks of age male mice were treated with 2
mg/ml of doxycycline in 2.5% sucrose water ad libidum, then were kept in a
washout period of 1 week (T0, Pax2/FUCCI2aR n= 4, Pax8/FUCCI2aR n= 4).
The percentage of induction was deﬁned in healthy mice as the number of Pax8-
lineage-positive cells expressing mCherry or mVenus on the total number of
tubular cells per ﬁeld. After the washout period male mice underwent a unilateral
IRI of 30 min (same procedure performed in Confetti mice), and were then killed at
day 2 (Pax2/FUCCI2aR n= 4, Pax8/FUCCI2aR n= 4) and at day 30 (Pax2/
FUCCI2aR n= 9, Pax8/FUCCI2aR n= 9). Animals with identical genotype and
similar age were assigned to experimental groups in a blinded manner. To verify if
the transgenic system exhibited any type of leakage or non-speciﬁc transgene
expression, Pax8/FUCCI2aR and Pax2/FUCCI2aR mice without induction were
killed at T0 and at day 30 after IRI (n= 3 for each transgenic mouse at each time
point).
All animals were killed by CO2 chamber and kidneys were collected and
evaluated by confocal microscopy or by ﬂow cytometry. To perform confocal
analysis kidneys were processed as described for Confetti mice.
Genotyping. Tail biopsies were incubated overnight at 55 °C in lysis reagent (1M
Tris-HCl, pH 8.5; 0.5 M EDTA, 20% SDS, 4M NaCl, 0.1 mg/ml proteinase K
neutralized with 40 mM Tris-HCl, all from Sigma-Aldrich), centrifuged and DNA
extracted using isopropanol (Sigma-Aldrich). To distinguish transgene homo-
zygosity from heterozygosity, qRT-PCR were performed by using 5 ng/µl of
genomic DNA with LightCycler® 480 SYBR Green I Master (Roche Diagnostics,
Rotkreuz, Switzerland). The reactions were performed using a LightCycler® 480
(Roche Diagnostics) with a program consisting of 40 cycles each constituted of an
initiation phase at 95 °C for 15 min, annealing phase at 60 °C for 45 min and
ampliﬁcation phase at 72 °C for 60 min. The following primers were used:
Fig. 7 Pax2 lineage-positive cells proliferate, while other TEC endocycle and are persistently lost after AKI. a Schematic procedure. b–j FACS analysis shows
mCherry+ and mVenus+ cells in total renal cells of Pax8/FUCCI2aR (b, d) and Pax2/FUCCI2aR mice (c, d) at T0, of Pax8/FUCCI2aR (e, g) and Pax2/
FUCCI2aR mice (f, g) at IRI T2 and of Pax8/FUCCI2aR (h, j) and Pax2/FUCCI2aR mice (i, j) at IRI T30. A representative experiment out of 4 is shown. k
Number of total FUCCI2aR cells in Pax8/FUCCI2aR and Pax2/FUCCI2aR mice at T0, IRI T2, IRI T30 (n= 4 in each group). Mann–Whitney test *p < 0.05. l
Number of new FUCCI2aR cells in Pax8/FUCCI2aR and Pax2/FUCCI2aR mice at IRI T30 in comparison to IRI T2 (n= 4 in each group). Mann–Whitney test
NS.m Percentage of Pax2/FUCCI2aR over Pax8/FUCCI2aR total cells at T0, IRI T2, IRI T30 (n= 4 in each group). Mann–Whitney test *p < 0.05. n Number
of total mVenus+ cells mCherry+mVenus+ cells in Pax8/FUCCI2aR and Pax2/FUCCI2aR mice at T0, IRI T2, IRI T30 (n= 4 in each group).
Mann–Whitney test NS. o, p Cell cycle distribution of mCherry+, mVenus+, and mCherry+mVenus+ cells in Pax8/FUCCI2aR (o) and Pax2/FUCCI2aR
mice (p) at IRI T30. A representative experiment out of 4 is shown. q Percentage of endocycling cells in Pax2/FUCCI2aR (black column) and Pax8/
FUCCI2aR mice (light gray column) at IRI T30 (n= 4 in each group). Mann–Whitney test *p < 0.05. r mCherry+ cells (red) and p-H3+ cells (blue) in LTA
+ tubules in the cortex (white) of Pax8/FUCCI2aR mice at IRI T30 (n= 5). Arrows show mCherry+p-H3+ cells. r′ Detail of r. s mCherry+ cells (red) and
mVenus+ cells (green) in LTA+ tubules in the cortex (white) of Pax8/FUCCI2aR mice at IRI T30 (n= 5). Arrow shows mVenus+ cell. t Percentage of
endocycling cells (mCherry+p-H3+ cells) and cycling cells (mVenus+ cells) in the cortex of Pax8/FUCCI2aR mice at IRI T30 (n= 5). Mann–Whitney test
*p < 0.05. u Percentage of endocycling (mCherry+p-H3+ cells) and cycling (mVenus+ cells) AQP2− cells in the cortex and in OSOM of Pax8/FUCCI2aR
mice at IRI T30 (n= 5). Mann–Whitney test *p < 0.05. v Measurement of the cell surface area of mCherry+p-H3+ cells and of mCherry+p-H3− cells
after staining with Phalloidin (white) with Image J software in Pax8/FUCCI2aR mice at IRI T30 (n= 4). w Cell surface area of mCherry+p-H3+ cells and of
mCherry+p-H3− cells in Pax8/FUCCI2aR mice at IRI T30. n= at least 20 cells for each mouse (n= 4), Mann–Whitney test ***p < 0.001. Data are mean ±
SEM. Scale bars 20 µm. T0= day 0, IRI T2= day 2 after IRI, IRI T30= day 30 after IRI
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Fig. 8 High percentage of endocycling TECs in the kidney of patients that developed CKD after AKI. a A healthy kidney section showing the expression of
CDK4 (green) and p-H3 (red) in LTA+ proximal tubular cells (blue) (n= 4). b–d A renal biopsy section from a patient that developed CKD after AKI (n=
7) showing CDK4+p-H3+ (green and red cells, arrows) and CDK4−p-H3+ (red cells, arrowheads) or CDK4+p-H3− (green cells, arrowheads) in
proximal tubular LTA+ cells (blue). d′ Split images of the tubule shown in d. e Percentage of CDK4+p-H3+LTA+ cells over total proximal TECs (LTA+) in
healthy kidneys (n= 4) and in renal biopsies from patients that developed CKD after AKI (n= 7). Mann–Whitney test *p < 0.05. f Percentage of CDK4+p-
H3+ cells over total TECs in healthy kidneys (n= 4) and in renal biopsies from patients that developed CKD after AKI (n= 7). Mann–Whitney test *p <
0.05. g, g′ A renal biopsy section from a patient that developed CKD after AKI (n= 8) showing the presence of two or three Y chromosome-probe (green)
in TECs labeled with Phalloidin (red), at different magniﬁcations. Arrowheads indicate doubled dots for Y chromosome in a nucleus. h High magniﬁcation of
another biopsy ﬁeld. Arrowhead indicates triple dots for Y chromosome in a nucleus. DAPI counterstains nuclei. Data are mean ± SEM. Scale bars 20 µm
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Pax2.rtTA and Pax8.rtTA forward 5′-AACGCACTGTACGCTCTGTC-3′ and
reverse 5′-GAATCGGTGGTAGGTGTCTC-3′; TetO.Cre forward 5′-
TCGCTGCATTACCGGTCGATGC-3′ and reverse 5′-
CCATGAGTGAACGAACCTGGTCG-3′. TCRα genomic DNA was used as gene
housekeeping for relative quantiﬁcation and was ampliﬁed by using the forward 5′-
CAAATGTTGCTTGTCTGGTG-3′ and the reverse 5′-
GTCAGTCGAGTGCACAGTTT-3′ primers.
To distinguish FUCCI2aR and Confetti homozygosity from heterozygosity,
PCR were performed with the following primers and parameters: Confetti forward
5′-GAATTAATTCCGGTATAACTTCG-3′ and reverse 5′-
AAAGTCGCTCTGAGTTGTTAT-3′, 3 min 94 °C, 35 cycles of 30 s 94 °C, 30 s 58 °
C, 30 s 72 °C and, ﬁnally, 2 min 72 °C; FUCCI-P3 5′-
TCCCTCGTGATCTGCAACTCCAGTC-3′, FUCCI-P4 5′-
AACCCCAGATGACTACCTATCCTCC-3′ and FUCCI-P4 5′-
GGGGGAGGATTGGGAAGACAATAGC-3′; 2 min 96 °C, 35 cycles of 96 °C 30 s,
65 °C 30 s and, ﬁnally, 72 °C for 30 s.
Renal ischemia reperfusion injury. Male mice were anesthetized by intraper-
itoneal injection of Ketamine (100 mg/kg)/Xylazine (10 mg/kg, Bio98 S.r.L, Milan,
Italia), which produced short-term surgical anesthesia with good analgesia. The
animals were kept warm in a 37 °C ventilated heating chamber before surgery and
their body temperature was monitored constantly by a rectal probe and maintained
in the range of 36.5–37 °C. The mouse was placed on a thermostatic station laying
on the right side, shaved and disinfected with Povidone-iodine and an incision of
1–1.5 cm on the skin on the left side was performed, then the muscle layer below
was cut and opened. The left kidney was then externalized pushing it out from the
cut with sterile cotton swabs to expose the renal pedicle for clamping. The renal
artery was clamped to block blood ﬂow to the kidney and cause ischemia (visible by
color change of the kidney from red to dark purple). The duration of kidney
ischemia starts from the time of clamping. After veriﬁcation of the color changes,
the kidney was returned to the abdomen cavity and the animal returned to the
ventilated heating chamber. The duration of ischemia was 30 min, after which the
clamp was removed to start the reperfusion, which is indicated by the change of
kidney color back to red. The muscle layer was sutured, followed by the closure of
the skin wound with metal clips. Immediately after the wound closure, 0.5 ml warm
sterile saline (0.9% NaCl) was given subcutaneously to each mouse to rehydrate it.
The right contralateral kidney was maintained untouched as a control.
Sham-operated mice underwent the same surgical procedure as above, but did
not experienced left renal artery clamping and did not suffered of ischemia.
Nephrotoxic AKI. Transgenic female mice were induced for 10 days with doxycy-
cline, held 1 week in washout, following which rhabdomyolysis-induced AKI was
performed, by intramuscular injection on day 0 with hypertonic glycerol (8ml/kg
body weight of a 50% glycerol solution; Sigma-Aldrich) into the inferior hind limbs.
Transcutaneous measurement of glomerular ﬁltration rate. Measurement of
the glomerular ﬁltration rate (GFR) was done as described elsewhere42. In brief,
mice (n= 9 Pax2/Confetti ischemic mice, n= 13 Pax8/Confetti ischemic mice,
n= 5 Pax8/Confetti sham-operated mice, n= 5 Pax2/Confetti sham-operated
mice, n= 5 Pax8/Confetti healthy mice, n= 5 Pax2/Confetti healthy mice, n= 7
Pax8/Confetti glycerol-treated mice, n= 8 Pax2/Confetti glycerol-treated mice,
n= 7 Pax2/Confetti ischemic mice treated with DMSO, n= 6 treated with PBS,
n= 7 treated with TSA, n= 6 treated with PBA) where anesthetized with
isoﬂurane and a miniaturized imager device built from two light-emitting diodes, a
photodiode and a battery (Mannheim Pharma and Diagnostics GmbH, Mannheim,
Germany) were mounted via a double-sided adhesive tape onto the shaved animals’
neck. For the duration of recording (~1.5 h) each animal was conscious and kept in
a single cage. Prior to the intravenous injection of 150 mg/kg FITC-sinistrin
(Mannheim Pharma and Diagnostics GmbH), the skin’s background signal was
recorded for 5 min. After removing the imager device, the data were analyzed using
MPD Studio software ver.RC6 (MediBeacon GmbH Cubex41, Mannheim, Ger-
many)43. The GFR [µl/min] was calculated from the decrease of ﬂuorescence
intensity over time (i.e., plasma half-life of FITC-sinistrin) using a two-
compartment model, the animals body weight and an empirical conversion factor.
For each time point, GFR value was normalized on the value at baseline and on the
sham (for ischemic mice) or healthy mice of comparable age and weight (for
glycerol-treated mice) value. Based on the results obtained in preliminary experi-
ments to assess GFR measurement variability, only mice showing a drop of GFR
after AKI of at least 20% over baseline were included in the study.
Estimation of blood urea nitrogen. Renal function was assessed by collecting a
small amount of blood from mice (n= 5 Pax8/Confetti ischemic mice, n= 5 Pax8/
Confetti sham-operated mice, n= 6 Pax8/Confetti glycerol-treated mice, n= 5
Pax8/Confetti healthy mice, n= 8 Pax2/Confetti glycerol-treated mice, n= 5 Pax2/
Confetti healthy mice) with a metal lancet from submandibular plexus at different
time points in order to measure BUN levels. Blood parameters were measured in
EDTA anticoagulated plasma samples using Urea FS kit (DiaSys Diagnostic Sys-
tems, Holzheim, Germany), according to the manufacturer’s protocols.
Assessment of renal injury. Healthy and ischemic kidneys stored in 4% buffered
formalin were embedded in parafﬁn and 2–4 µm sections were prepared for per-
iodic acid–Schiff (PAS) staining. Ischemic tubular injury and scaring were eval-
uated by assessing the percentage of tubules in the outer stripe of outer medulla
that displayed cell necrosis, tubular dilatation or cast formation (injury), atubular
sections with abundant unorganized parenchyma cells and cell inﬁltrates (scar-
ring). Twenty-four kidneys from Pax2/Confetti mice and 4 ﬁelds (20×) per kidney
were analyzed. All assessments were performed by a blinded observer.
Immunoﬂuorescence and confocal microscopy. Confocal microscopy was per-
formed on 10 μm sections of renal tissues by using a Leica SP5 AOBS confocal
microscope (Leica, Wetzlar, Germany) equipped with a Chameleon Ultra-II two-
photon laser (Coherent, Milan, Italy).
The following antibodies were used: anti-aquaporin-1 (AQP1, AB2219, dilution
1:100, Millipore, Darmstadt, Germany), anti-Tamm-Horsfall (THP, CL1032A,
dilution 1:20, Cederlane, Burlington, Ontario, Canada), anti-aquaporin-2 (AQP2,
C-17, SC-9882, diluition 1:25, Santa Cruz Biotechnology, Saint Louis, USA), anti-
megalin (P-20, sc-16478, diluition 1:25, Santa Cruz Biotechnology), biotinylated
Lotus Lectin, LTA (B-1325, dilution 1:50, Vector Laboratories, Burlingame, USA),
anti-KIM-1 (AF1817, dilution 1:40, R&D Systems, Inc., Minneapolis, USA), anti-
Pax2 (71–6000, dilution 1:25, Zymed, Thermo Fisher Scientiﬁc, MA USA) anti-Ki-
67 (ab15580, dilution 1:50, Abcam, Cambridge, UK), anti-GFP-488 (A21311,
dilution 1:100, Life Technologies, Monza, Italy), anti-phosphorylated Histone 3 (p-
H3, ab14955, dilution 1:2000, Abcam), anti-cyclin dependent kinase 4 (CDK4, SC-
601, dilution 1:50, Santa Cruz Biotechnology) and Phalloidin-633 (A22284,
dilution 1:40, Life Technologies). Alexa-Fluor secondary antibodies were obtained
Table 1 List of patients with CKD after AKI analyzed in this study
Patient Gender Age (years) Diagnosis Number and severity of AKI
episode(s)
CKD stage Time since last AKI episode(s) and
biopsy (days)
1. M 10 TIN 1× AKIN3 CKD2 45
2. M 5 IRI 2× AKIN3 CKD3 180
3. M 59 IRI 3× AKIN1 CKD4 365
4. M 56 Sepsis 1× AKIN3 CKD4 30
5. M 73 Light chain ATN 1× AKIN1, 1× AKIN2 CKD4 365
6. M 57 IRI 1× AKIN3 CKD4 730
7. F 55 IRI 1× AKIN1, 2× AKIN2 CKD4 270
8. F 30 IRI 1× AKIN3 CKD3 1460
9. M 56 IRI 1× AKIN3 CKD4 45
10. M 38 IRI 1× AKIN2 CKD3 30
11. M 44 RCC-normal tissue None None
12. M 86 RCC-normal tissue None None
13. M 26 RCC-normal tissue None None
14. M 74 RCC-normal tissue None None
15. F 51 RCC-normal tissue None None
TIN tubulointerstitial nephritis, IRI ischemia reperfusion injury, ATN acute tubular necrosis, AKIN Acute Kidney Injury Network criteria, number indicates stage, CKD chronic kidney disease, number
indicates stage, RCC renal cell carcinoma
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from Molecular Probes (Life Technologies). For the detection of tubules, staining
with Alexa Fluor 546 Phalloidin (A22283, dilution 1:40, Molecular Probes, Life
Technologies) was performed. For the Pax8/Confetti mice and for Pax2/Confetti
mice the acquisition was set in the cyan, green, yellow, and red wavelengths using
405, 488, 514, and 543 nm wavelength excitation, respectively. For Pax8/FUCCI2
mice, Pax2/FUCCI2, Pax8/FUCCI2aR, and Pax2/FUCCI2aR mice the acquisition
was set in green and red wavelengths using 488, and 543 nm excitation,
respectively. mCherry emission was collected through 570/620 nm BP. Nuclei were
counterstained with DAPI (62248, dilution 1:1000, Life Technologies) excited with
Chameleon Ultra-II two-photon laser at 800 nm.
Cell surface area of at least 20 mCherry+p-H3− cells and 20 mCherry+p-H3+
cells for each Pax8/FUCCI2aR mouse were measured using Image J software. One
ﬁeld is: 620 × 620 µm.
3D reconstruction. To generate 3D images (Fig. 4g–i) and Supplementary
Movie 1, an image processing software from Leica Microsystems “Leica Applica-
tion Suite X” was used. Z-series stacks were obtained from 40 µm kidney slices,
being this thickness the limit to stain all the nuclei with DAPI, permitting cell
counting. Images were collected at 1 µm intervals. Clones were observed in every
color, but for 3D reconstruction, we chose mostly the yellow ones cause the YFP is
distributed in all the cell, making the 3D reconstruction easier to build and
appreciate.
To compare 2D with 3D analysis, two blinded observers counted the number of
clones in 2D images and in 3D reconstruction. The percentage of clonogenic cells
was calculated as reported below (Eq. 2).
Immunohistochemistry. Immunohistochemistry for PCNA was performed in
parafﬁn embedded healthy and ischemic kidney sections (n= 5 at day 0, n= 5 at
day 2 and at day 30 after IRI), as detailed elsewhere44. Brieﬂy, after removing the
parafﬁn and rehydrating in water, the tissue sections were submerged in 3% H2O2
for 10 min to block the endogenous peroxidase activity. The target antigen was
retrived by microwaving the sections in sodium citrate buffer (10 mM, pH 6). The
samples were heated in a microwave at 800W for 3 min and then for 7 min at 400
W. The sections were cooled for 30 min at room temperature. After that, the 10-
min heating procedure was repeated with fresh buffer. Sections were pre-incubated
for 30 min in 1× PBS, 1% bovine serum albumin, 0.05% saponin and subsequently
incubated for 15 min at 37 °C and overnight at 4 °C with mouse anti-PCNA (PC10,
ab29, dilution 1:300, Abcam). Then, sections were incubated for 1 h at room
temeperature with secondary biotynilated-anti mouse IgG antibody, followed by an
incubation with avidin-biotin-peroxidase complex (Vectastain ABC kit, Vector
Laboratories) for 30 min, and 3-amino-9-ethylcarbazole (AEC, Vector Labora-
tories) (red color) as peroxidase substrate for 20 min. Sections were counterstained
with Eosin G (Bioptica, Milan, Italy).
Clone frequency analysis. Single-cell clones and clones with two or more cells
were counted in AQP2− tubules of the outer stripe of outer medulla in Pax8/
Confetti mice at day 0 (T0), in age-matched controls (T30), in sham operated, in
ischemic kidneys (IRI T30) and in nephrotoxic kidneys (Gly T30).
For each clone size, clone frequency analysis showed in Fig. 1j, was assessed as
followed:
Clone frequency ð%Þ ¼ ðn of clones of n cells=total n of clonesÞ ´ 100; ð1Þ
where 1 ≤ n ≤ 11 in Pax8/Confetti mice because this is the maximum clone size
observed.
Same calculations were performed in Pax2/Confetti mice at T0, T30, sham
operated and IRI T30 where 2 ≤ n ≤ 10 (Fig. 3f)
Clones observed in a total of at least 30 ﬁelds of outer stripe of the outer
medulla taken from at least ﬁve sections of each mouse were counted by two
independent blinded observers. Clone size was established by counting the nuclei
counterstained with DAPI.
See Supplementary Methods for a representative calculation.
Clonogenic cell analysis. To establish the percentage of clonogenic cells in Pax8/
Confetti mice we performed the following calculations:
(A) n° of new clones at day 30 after IRI (IRI T30)=
X11
n¼2
clones composed of n cells at IRI T30 clones composed of n cells at T0ð Þ;
where 2 ≤ n ≤ 11 in Pax8/Confetti mice because the maximum clone size observed
is 11 cells.
(B) % of clonogenic cells at IRI T30 in comparison to T0 (vs. T0) showed in
Fig. 1l.
A=n of Pax8þcells at T0ð Þ ´ 100: ð2Þ
Same calculations were performed in Pax2/Confetti mice where 2 ≤ n ≤ 10
(Fig. 3j).
Same calculations were performed in Pax8 and Pax2 Confetti mice 30 days after
nephrotoxic AKI (Gly T30, Fig. 1l, Fig. 3n).
Same calculations were performed for 3D analysis in Pax8 and Pax2 Confetti
mice at IRI T30 (Fig. 4f)
All the analysis was performed in tubular cells excluding collecting ducts (AQP2
immunostained) of the outer stripe of outer medulla. All counts were executed by
two independent blinded observers.
See Supplementary Methods for a representative calculation.
Percentage of new cells after ischemic or nephrotoxic AKI. To establish the
percentage of new cells in Pax8/Confetti mice at IRI T30 we performed the fol-
lowing calculations (Fig. 1k):
(C) n° of Pax8+ cells included in clones at IRI T30
X11
n¼2
½ clones composed of n cells at IRI T30 clones composed of n cells at T0ð Þ ´ n;
where 2 ≤ n ≤ 11 in Pax8/Confetti mice because the maximum clone size observed
is 11 cells.
(D) n° of new Pax8+ cells at IRI T30= n° of Pax8+ cells included in new
clones–n° of cells that originated new clones*
C  A
* the n° of cells that originated new clones coincides with the n° of new clones at
IRI T30 (A), because each clone is the progeny of one cell.
(E) % of new Pax8+ cells at IRI T30 in comparison to T0
ðD=n of Pax8þcells at T0Þ ´ 100: ð3Þ
Same calculations were performed in Pax8/Confetti mice after nephrotoxic AKI
(Fig. 1k) and in Pax2/Confetti mice at day 30 after IRI (Fig. 3g). In Pax2/Confetti
mice 2 ≤ n ≤ 10.
All the analysis was performed in tubular cells excluding collecting ducts (AQP2
immunostained) of the outer stripe of outer medulla. All counts were executed by
two independent blinded observers.
See Supplementary Methods for a representative calculation.
Percentage of lost cells after ischemic or nephrotoxic AKI. To establish the
percentage of lost cells in Pax2/Confetti mice after ischemic AKI, we performed the
following calculations (Fig. 3i):
100 n of Pax2þcells at IRI T30 D=n of Pax2þcells at T0ð Þ ´ 100½ : ð4Þ
Same calculations were performed in Pax8/Confetti mice after ischemic AKI
(Fig. 3i) and in Pax2/Confetti and Pax8/Confetti mice after nephrotoxic AKI
(Fig. 3m).
All the analysis was performed in tubular cells excluding collecting ducts (AQP2
immunostained) of the outer stripe of outer medulla. All counts were executed by
two independent blinded observers.
See Supplementary Methods for a representative calculation.
Percentage of variation over T0. To establish the percentage of variation over T0
in Pax2/Confetti mice after ischemic AKI, we performed the following calculations
(Fig. 3k):
n of Pax2þcells at IRI T30=n of Pax2þcells at T0ð Þ ´ 100½   100: ð5Þ
Same calculations were performed in Pax8/Confetti mice after ischemic AKI
(Fig. 3k) and in Pax2/Confetti and Pax8/Confetti mice after nephrotoxic AKI
(Fig. 3o).
All the analyses were performed in tubular cells excluding collecting ducts
(AQP2 immunostained) of the outer stripe of outer medulla. All counts were
executed by two independent blinded observers.
Percentage of variation of Pax2+ cells and Pax2− cells over IRI. To establish
the percentage of variation of Pax2+ cells over IRI in Pax2/Confetti mice after
ischemic AKI and treatment with TSA or 4-PBA, we performed the following
calculations (Fig. 5e):
n of Pax2þcells after treatment at IRI T30=n of Pax2þcells at IRI T30ð Þ ´ 100½ :
ð6Þ
Same calculations were performed for Pax2− cells (Fig. 5e). All counts were
executed by two independent blinded observers.
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Frequency of Pax2+ clones. This analysis was performed in the cortex after
megalin immunostaining, in the OSOM after AQP1 and THP immunostaining and
in the collecting ducts after AQP2 immunostaining.
To establish the frequency of Pax2+ clones in nephron segments and in
collecting ducts, we performed the following calculations (Fig. 4e):
(F) n° of total Pax2+ new clones at day 30 after IRI (IRI T30)=
n of newmegalinþclonesþ n of new AQP1þ clones
þn of new THPþ clonesþ n of new AQP2þclones :
The n° of new clones was determined based on the calculation used in
formula A.
(G) frequency of Pax2+ clones (%) in each nephron segment and in collecting
ducts=
A=Fð Þ ´ 100: ð7Þ
Cell cycle analysis by ﬂow cytometry. Cell cycle analysis was performed on total
FUCCI2 cells and on total FUCCI2aR cells (mCherry+ and mVenus+ cells) in
Pax8/FUCCI2 mice, in Pax2/FUCCI2 mice, in Pax8/FUCCI2aR mice, and in Pax2/
FUCCI2aR mice at 2 days and at 30 days after IRI.
Pax8/FUCCI2, Pax8/FUCCI2aR, Pax2/FUCCI2, and Pax2/FUCCI2aR kidneys
were processed in order to obtain a single cell suspension and to perform cell cycle
analysis by ﬂow cytometry. To this aim, kidneys were minced using a scalpel. After
addition of 1.5 ml of digestion buffer (300 U/ml Collagenase II and 1 mg/ml
Pronase E, Sigma-Aldrich) they were incubated at 37 °C for 20 min. The solution
was pipetted up and down with a cut 1000 µl pipette tip every 5 min. The digested
kidneys were gently pressed through a graded mesh screen (150 mesh, Sigma-
Aldrich) and the ﬂow through was washed extensively with HBSS (Life
Technologies). After spinning down, the supernatants were discarded and the
pellets digested again with digestion buffer at 37 °C for 20 min. During this
incubation period the suspensions were sheared with a 27-G needle. Erythrocytes
were lysed with NH4Cl 0.8%. Single-cell suspensions were ﬁxed with 1% PFA for 1
h at RT and with 70% ethanol overnight. Then cells were stained as described
elsewhere45. Incubation with anti-DsRed pAb (632496, dilution 1:25, Clontech,
Mountain View, CA, USA) or isotype control was followed by incubation with
Alexa Fluor 647 goat anti-rabbit as secondary antibody to detect mCherry+ cells,
whereas for detection of mVenus+ cells was used an anti-GFP-488 pAb (A21311,
dilution 1:100, Life Technologies). Cells were, then, incubated with DAPI to
perform the DNA content analysis. In order to verify if similar results were
obtained after depletion of AQP2+ cells, Pax8/FUCCI2 mouse kidneys (n= 3)
were processed as above and cells were ﬁxed with 1% PFA for 1 h at RT. An aliquot
of cells was incubated with anti-AQP2 pAb (bs-4611R, dilution 1:20, Bioss Inc.,
Woburn, Massachusetts) or with isotype control and with Alexa Fluor 647 goat
anti-rabbit as secondary antibody (Life Technologies). The remaining part of the
cells were incubated with anti-AQP2 pAb (bs-4611R, dilution 1:20, Bioss Inc.)
followed by anti-rabbit MicroBeads (Miltenyi Biotec S.r.l.), then passed through
MS columns (Miltenyi Biotec S.r.l.) accordingly with the manufacturer’s protocol
and collecting the ﬁrst ﬂow-through containing unlabeled cells in order to perform
a magnetic cell depletion of AQP2+ cells. A small part of both the depleted- or
not-depleted AQP2 cell fractions were stained with AQP2 pAb (bs-4611R, dilution
1:20, Bioss Inc.) followed by an Alexa Fluor 647 goat anti-rabbit as secondary
antibody and then analyzed by Cytoﬂex S instrument (Beckman Coulter, Brea, CA)
with CytExpert software. AQP2-depleted cell fraction was ﬁxed with 70% ethanol
overnight and the day after was stained with anti-DsRed pAb (632496, dilution
1:25, Clontech) and anti-GFP pAb (A21311, dilution 1: 100, Life Technologies) as
above to evaluate mCherry+ cells and mVenus+ cells. More than 50,000 events
were analysed in each experiment by using a FACS LSRII instrument (BD
Biosciences, San Jose, CA) with the FACSDiva software or by using Cytoﬂex S
instrument (Beckman Coulter) with CytExpert software. More than 50,000 events
were analysed in the experiments with Pax8/FUCCI2aR and Pax2/FUCCI2aR mice
by using a FACS LSRII instrument (BD Biosciences) and a MacsQuant instrument
(Miltenyi Biotec S.r.l.). The assessment of the total number of Pax8/FUCCI2aR and
Pax2/FUCCI2aR cells was performed by using a MacsQuant instrument (Miltenyi
Biotec S.r.l.). Alexa Fluor 647 secondary antibody was excited by a 633 nm laser
line, GFP pAb was excited by a 488 nm laser line, DAPI was excited by a UV laser
at 355 nm.
Tissues. A total of 5 healthy kidneys (4 men and 1 woman, mean age 56.2 ± 11)
and 10 renal biopsies from patients (mean age 43.7 ± 7.2) that developed CKD after
AKI were analyzed in agreement with the Ethical Committee on human experi-
mentation of the Azienda Ospedaliero-Universitaria Careggi and of the Meyer
Children’s University Hospital, Florence, Italy. Normal kidney fragments were
obtained from the pole opposite to the tumor of patients who underwent
nephrectomy for localized renal tumors. Formal consents were obtained by the
donors or relatives. The AKI stage was classiﬁed according to KDIGO Guidelines46.
The list of patients with CKD after AKI analyzed in this study is reported in
Table 1.
Fluorescence in situ hybridization analysis. Fluorescence in situ hybridization
analysis was performed using Whole Chromosome Painting Probe for Y chro-
mosome (FITC) (Cytocell Ltd, Tarrytown, NY, USA) following the manufacturer’s
instructions in combination with Phalloidin-546 (A22283, dilution 1:40, Life
Technologies).
Study approval. Animal experiments were approved by the Institutional Review
Board and by the Italian Ministery of Health and by the Ethical Committee of the
“Regierung von Oberbayern” and performed in accordance with institutional,
regional, and state guidelines and in adherence to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Mice were housed in a speciﬁc
pathogen-free facility with free access to chow and water and a 12-h day/night
cycle.
Statistical analysis. The results were expressed as mean ± SEM. Comparison
between groups was performed by the Mann–Whitney U-test, or through the
analysis of variance for multiple comparisons (ANOVA for repeated measures)
with Tukey post hoc analysis. p < 0.05 was considered to be statistically
signiﬁcant.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information Files or
from the corresponding author upon reasonable request.
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